Advertisement

Topics

Expert Highlights Evolving Options in HER2+ Breast Cancer

09:24 EST 15 Feb 2018 | OncLive

Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.

Original Article: Expert Highlights Evolving Options in HER2+ Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Expert Highlights Evolving Options in HER2+ Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...